Log in to save to my catalogue

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML ex...

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML ex...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6438937

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

About this item

Full title

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Publisher

Singapore: Springer Singapore

Journal title

International journal of clinical oncology, 2019-04, Vol.24 (4), p.445-453

Language

English

Formats

Publication information

Publisher

Singapore: Springer Singapore

More information

Scope and Contents

Contents

Background
Treatment-free remission (TFR), the ability to maintain a molecular response (MR), occurs in approximately 50% of patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs).
Methods
A multicenter phase 2 trial (Delightedly Overcome CML Expert Stop TKI Trial: DOMEST Trial) was conducted to tes...

Alternative Titles

Full title

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6438937

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6438937

Other Identifiers

ISSN

1341-9625,1437-7772

E-ISSN

1437-7772

DOI

10.1007/s10147-018-1368-2

How to access this item